Biora Therapeutics to Participate in Upcoming BTIG Investment Conference

SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) — Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today announced that the company’s management team will be participating in one-on-one meetings at the upcoming BTIG Biotechnology Conference, which is taking place both virtually and at the St. Regis New York Hotel in New York City, August 8-9, 2022.

For those interested in meeting with Biora at the conference, please reach out to your BTIG representative to schedule a meeting.

About Biora Therapeutics
Biora Therapeutics is the biotech company that is reimagining therapeutics. By creating innovative smart pills designed for targeted drug delivery to the GI tract, and systemic, needle-free delivery of biotherapeutics, the company is developing therapies to improve patients’ lives. Biora envisions a world where patients have access to needle-free drug delivery and better therapeutic outcomes.

For more information, visit bioratherapeutics.com or follow the company on LinkedIn or Twitter.

Safe Harbor Statement or Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this press release, including statements concerning the progress and future expectations and goals of our research and development efforts, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “plan” or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements reflect our plans, estimates, and expectations, as of the date of this press release. These statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this press release. Such risks, uncertainties, and other factors include, among others, our ability to innovate in the field of precision medicine, our ability to obtain and maintain regulatory approval or clearance of our products on expected timelines or at all, our plans to research, develop, and commercialize new products, the unpredictable relationship between preclinical study results and clinical study results, our expectations regarding future revenue generating opportunities with current or future pharmaceutical collaborators, our ability to raise sufficient capital to achieve our business objectives, the ongoing COVID-19 pandemic, and those risks described in “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC and other subsequent documents, including Quarterly Reports, that we file with the SEC.

Biora Therapeutics expressly disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.

Investor Contact
Chuck Padala
Managing Director, LifeSci Advisors
IR@bioratherapeutics.com
(646) 627-8390

Media Contact
media@bioratherapeutics.com

Staff

Recent Posts

WakeMed Selects Bamboo Health to Drive Improved Care Coordination for Patients

The collaboration will bring clinical insights across the patient health journey for over 320,000 annual…

1 min ago

Info-Tech LIVE 2024: Featured Experts Announced to Unveil Key 2025 AI, Next-Gen IT, and Tech Trends at September Event in Las Vegas

Info-Tech LIVE 2024 promises actionable insights and transformative strategies for IT leaders and professionals. The…

7 mins ago

TSI Names Angela Armstrong as Executive Vice President and General Manager of TSI Healthcare

LAKE FOREST, Ill., June 12, 2024 /PRNewswire/ -- Transworld Systems Inc. (TSI), the leading technology…

7 mins ago

PatientPoint Receives Global Recognition at 45th Annual Telly Awards

Digital health leader wins 13 creative awards for outstanding patient education content and engagement CINCINNATI,…

7 mins ago

Prendio-BioProcure and Portal Innovations Announce Strategic Partnership to Accelerate Life Science Innovation

BOSTON, June 12, 2024 /PRNewswire/ -- Prendio-BioProcure, a leading procurement platform tailored for the biotech…

7 mins ago

AxonDAO Unveils A+Voice: Pioneering Biometric AI Voice Collection

CHEYENNE, Wyo., June 12, 2024 /PRNewswire/ -- AxonDAO (Axon DAO LLC, Wyoming) proudly announces the launch…

7 mins ago